Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dimethyl Fumarate Delayed-Release Capsules, 120mg and 240mg. Aurobindo Pharma’s Dimethyl Fumarate Delayed-Release Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), TECFIDERA Delayed-Release Capsules manufactured by BIOGEN Inc.
Dimethyl Fumarate Delayed-Release Capsules, are indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Dimethyl Fumarate Delayed-Release Capsules, has an estimated market size of US $771 Million for the twelve months ending November 2022, as per IQVIA.
